Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
about
What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia.Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy.The political economy of the assessment of value of new health technologies.
P2860
Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Costs of paying higher prices ...... harmaceutical Benefits Scheme.
@en
Costs of paying higher prices ...... harmaceutical Benefits Scheme.
@nl
type
label
Costs of paying higher prices ...... harmaceutical Benefits Scheme.
@en
Costs of paying higher prices ...... harmaceutical Benefits Scheme.
@nl
prefLabel
Costs of paying higher prices ...... harmaceutical Benefits Scheme.
@en
Costs of paying higher prices ...... harmaceutical Benefits Scheme.
@nl
P356
P1476
Costs of paying higher prices ...... Pharmaceutical Benefits Scheme
@en
P2093
Laura Edney
P356
10.1071/AH15122
P577
2017-03-01T00:00:00Z